<DOC>
	<DOC>NCT03080740</DOC>
	<brief_summary>Randomized, double blind, positive drug parallel comparison, multi-centre clinical trial to assess the Efficacy and Safety of Clindamycin palmitate hydrochloride dispersible tablet for the treatment of bacterial vaginosis</brief_summary>
	<brief_title>The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis</brief_title>
	<detailed_description>Treatment group: Clindamycin palmitate hydrochloride dispersible tablet . Control group: Metronidazole Tablet.</detailed_description>
	<mesh_term>Vaginal Diseases</mesh_term>
	<mesh_term>Vaginosis, Bacterial</mesh_term>
	<mesh_term>Clindamycin</mesh_term>
	<mesh_term>Clindamycin palmitate</mesh_term>
	<mesh_term>Clindamycin phosphate</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>1. Patients clinically diagnosed with bacterial vaginosis, should meet the following criteria: vaginal Gram stain integration score (Nugent score) â‰¥7 points 2. Female patients aged 18 to 55 years old. 3. Patients signed the Informed Consent Form(ICF). 1. Patients with vulvovaginitis caused by other infectional reasons such as vaginitis vulvovaginal candidiasis, trichomoniasis vaginitis. 2. Patients received systemic or vaginal antimicrobial therapy in a week before enrolled. 3. Patients with other vaginal or vulvar disorders which could effect the evaluation of efficacy. 4. Pregnant or lactating patients. 5. Menopausal women. Menopause definition: perimenopausal women stop menstruations for a year. 6. Women with diabetes. 7. Dependent on alcohol and could not prohibit during the study period. 8. Women with liver and kidney disfunction, blood disorders, mental illness or other serious diseases. 9. Women allergic to metronidazole, clindamycin. 10. With poor compliance.</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>